Phenylketonuria (PKU) is inherited in an autosomal recessive pattern, meaning a child must receive one copy of a changed gene from each parent to have the condition. Both parents are typically carriers who have no symptoms themselves. When two carriers have a child, there is a 25% chance the child will have PKU, a 50% chance the child will be an unaffected carrier, and a 25% chance the child will neither have PKU nor carry the gene variant.
The Gene Behind PKU
PKU traces back to the PAH gene, located on chromosome 12. This gene carries the instructions for making an enzyme called phenylalanine hydroxylase, which converts the amino acid phenylalanine into another amino acid, tyrosine. When both copies of the PAH gene carry mutations, the enzyme either doesn’t work properly or isn’t produced at all. Phenylalanine then builds up in the blood and brain, causing damage if left untreated.
More than 1,500 different variants of the PAH gene have been cataloged in international databases. This is why PKU exists on a spectrum. Some mutations knock out enzyme activity almost entirely, causing classical (severe) PKU. Others leave some residual enzyme function, resulting in milder forms. The specific combination of mutations a person inherits from each parent helps determine how severe their condition will be.
What “Autosomal Recessive” Means in Practice
Everyone has two copies of the PAH gene, one from each biological parent. In autosomal recessive inheritance, a single working copy is enough to produce sufficient enzyme. That’s why carriers, people with one changed copy and one working copy, process phenylalanine normally and never know they carry the variant unless they’re tested.
PKU only appears when a child inherits a changed copy from both parents. This is why the condition can seem to appear “out of nowhere” in families with no known history. Both parents may have carried the variant for generations without anyone being affected, because a carrier only passes on the changed copy roughly half the time. It takes the unlikely pairing of two carriers, and then the 1-in-4 odds per pregnancy, for a child to be born with PKU.
Importantly, autosomal means the PAH gene sits on chromosome 12, not on a sex chromosome. PKU affects boys and girls equally.
The Math for Each Pregnancy
When both parents are carriers, the odds reset with every pregnancy. Each child independently has a:
- 25% chance of inheriting two changed copies and having PKU
- 50% chance of inheriting one changed copy and being an unaffected carrier
- 25% chance of inheriting no changed copies at all
If only one parent is a carrier and the other has no PAH variants, none of their children will have PKU. However, each child would have a 50% chance of being a carrier. If one parent actually has PKU (two changed copies) and the other is not a carrier, every child will be a carrier but none will have the condition. If one parent has PKU and the other is a carrier, each pregnancy carries a 50% chance of the child having PKU.
How Common Is Carrier Status?
PKU rates vary significantly across populations. The overall frequency in Europe is roughly 1 in 10,000 births, but some populations have much higher rates: about 1 in 4,500 in Ireland and 1 in 2,600 in Turkey. Higher disease incidence means carrier rates in those populations are also higher. In a population where PKU occurs in 1 in 10,000 births, roughly 1 in 50 people is a carrier.
A blood test can identify carriers. Genetic testing is typically offered to people who have PKU themselves, have a family member with PKU, or have a partner who is a known carrier. If you’re planning a pregnancy and PKU runs in your family, carrier screening before conception can clarify your risk.
Newborn Screening Catches PKU Early
Nearly all developed countries screen newborns for PKU through a heel-prick blood test done in the first few days of life. The test measures phenylalanine levels in the blood. When levels exceed a screening threshold (commonly around 120 micromol/L, or about 2 mg/dL), a second sample is taken. Babies with persistently elevated levels, particularly above 200 micromol/L, undergo genetic testing to confirm the diagnosis and identify the specific PAH mutations involved.
This screening exists because PKU causes no visible symptoms at birth. Without testing, the damage from accumulating phenylalanine would already be underway before parents or doctors noticed anything wrong. Early detection allows dietary treatment to begin within the first weeks of life, preventing intellectual disability and other complications almost entirely.
Maternal PKU: A Risk Beyond the Baby’s Genes
There’s an important scenario that goes beyond standard inheritance. When a woman who has PKU becomes pregnant, her elevated phenylalanine levels can harm the developing baby regardless of whether the baby has PKU. The placenta actually concentrates phenylalanine, exposing the fetus to levels 1.5 to 2 times higher than the mother’s own blood levels.
This is called maternal PKU syndrome. Babies born to mothers with poorly controlled phenylalanine during pregnancy face serious risks including intellectual disability, heart defects, abnormally small head size, and other birth defects. These problems happen because of the toxic prenatal environment, not because of the baby’s own genotype. The baby might only be a carrier, or might not carry any PAH variants at all, and still be affected.
Women with PKU who maintain strict dietary control of their phenylalanine levels before and throughout pregnancy can dramatically reduce these risks. This is why managing phenylalanine levels becomes especially critical during the reproductive years.
Severity Depends on the Specific Mutations
Because there are more than 1,500 known PAH variants, two people with PKU can have very different experiences. The combination of mutations you inherit, one from each parent, largely determines how much working enzyme your body produces. Some combinations leave virtually no enzyme activity, leading to classical PKU with very high phenylalanine levels requiring strict lifelong dietary restriction. Other combinations allow partial enzyme function, resulting in mild or moderate forms that may be easier to manage.
Some individuals with milder mutations respond to a supplemental form of a natural cofactor that the enzyme needs to function. This cofactor helps the partially functional enzyme work more efficiently, lowering phenylalanine levels enough to relax dietary restrictions somewhat. Genetic testing after diagnosis helps predict whether this treatment approach is likely to work, based on which specific mutations are present.